Jump to main content

TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 12 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 12 years of age.

Mobile site search icon.
Mobile navigation icon.

TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 12 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 12 years of age.

What is Takhzyro?

TAKHZYRO is a prescription
medicine that’s taken regularly
to
help prevent HAE attacks

A real TAKHZYRO® patient, Soraya having dinner table and laughing with her friends.
Soraya

In the 6.5-month clinical study, people
taking TAKHZYRO
300 mg every 2
weeks had

87%
fewer attacks on average compared with placebo
Check mark icon.

FEWER ATTACKS OR ZERO ATTACKS IN 2 CLINICAL STUDIES

A 6.5-month clinical trial and a 2.5-year open-label extension study.

MORE STUDY INFO

Check mark icon.

SELF
ADMINISTRATION

1 subcutaneous self injection every 2 weeks.

Get Dosing Info

Check mark icon.

EFFECTIVE
PREVENTION

Speak with your doctor to see
if TAKHZYRO is right for you.

Talk to your doctor

In a 6.5-month clinical study of 125 people with HAE 12 years of age and older, TAKHZYRO significantly reduced the number of monthly attacks, compared with placebo. According to a supportive analysis, there were people taking TAKHZYRO who had zero attacks during the entire 6.5-month clinical trial. In the 2.5-year, long-term, open-label study with 212 people with HAE 12 years of age and older, people taking TAKHZYRO had similar results when comparing attack rates before beginning treatment in either the clinical trial or the long-term, open-label study. Long-term safety of TAKHZYRO was the primary endpoint in the open-label extension study.

The recommended dose is 300 mg every 2 weeks for people starting on TAKHZYRO.

If you have zero attacks for more than 6 months, your doctor may consider prescribing TAKHZYRO 300 mg once every 4 weeks.

View Transcript

For some, effective prevention means going from several attacks a week to periods of months with zero attacks. For others, it means only having to take TAKHZYRO once every 2 weeks. What does effective prevention mean to you?

SCOTT: Effective prevention means not just reducing the amount of HAE attacks I have, but also having to take TAKHZYRO just once every two weeks.

DENNIS: Effective prevention means it has the potential to reduce the frequency of my HAE attacks. With TAKHZYRO, not only am I having fewer attacks, but they're also less severe.

SORAYA: I used to have three HAE attacks a week and felt like I was spending half my life in the hospital. Now, I'm having periods of as long as two months with zero attacks, thanks to TAKHZYRO. Which is great because for me, even one attack is too many.

KELLY: Before preventive treatment, I felt like I could have an HAE attack at any moment. But in the last 12 months, I've only had one attack. That's incredible. I feel like now that I'm having fewer attacks, I've reached a new normal.

JACK: Years ago, HAE attacks forced me to quit my job. Reducing the frequency of my HAE attacks has helped me to focus on my career as a nurse.

ANDREW: Before I started preventive treatment, if I had an HAE attack, I would basically try my best to manage it in the moment. I would treat the swell reactively with my on-demand medicine and just wait for it to go down. Now that I'm taking TAKHZYRO, I know there's a way to help prevent my HAE attacks.

NARRATOR: TAKHZYRO (lanadelumab) is a prescription medicine used to prevent attacks of hereditary angioedema, HAE, in people 12 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 12 years of age. TAKHZYRO may cause serious side effects including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms: wheezing, difficulty breathing, chest tightness, fast heartbeat, faintness, rash, and/or hives.

NARRATOR: The most common side effects seen with TAKHZYRO were injection site reactions: pain, redness, and bruising; upper respiratory infection and headache. These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to the FDA at 1-800-FDA-1088. TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

NARRATOR: Talk to your healthcare provider about TAKHZYRO, the only preventive HAE treatment you take as a subcutaneous injection just once every two weeks.

Down arrow icon.

Are you ready to reimagine your life with fewer HAE attacks?

You might be interested to know TAKHZYRO was evaluated first in a 6.5-month clinical study, and similar results were observed in a 2.5-year, long-term open-label extension study.

see study results
TAKHZYRO+YOU logo.

WANT TO LEARN MORE?

Attending a TAKHZYRO+YOU event is a great way to learn and discover more about TAKHZYRO. You'll hear from healthcare professionals as well as people taking TAKHZYRO.

FIND EVENTS